The different patterns of immune memory cell differentiation between HFRT + PD-1 and chemo-immunotherapy suggest that sequential radio-chemo-immunotherapy could promote comprehensive stimulation of immune memory, and thus might bring greater clinical benefit to patients with NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.